Skip to main content
SpringerPlus

Table 2 Demographic and baseline characteristics: safety population

From: Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer

Treatment

TAC + Bevacizumab (n = 92)

TCH + Bevacizumab (n = 34)

Total (N = 126)

Gender, female, n (%)

92 (100.0)

34 (100.0)

126 (100.0)

Age, years

   

 n

92

34

126

 Mean

50.7

49.9

50.5

 SD

10.09

9.38

9.88

 Median

51.5

51.5

51.5

 Min, max

28, 70

26, 65

26, 70

Age group, years, n (%)

   

 < 65

84 (91.3)

33 (97.1)

117 (92.9)

 ≥ 65

8 (8.7)

1 (2.9)

9 (7.1)

Race, n (%)

   

 Caucasian

82 (89.1)

23 (67.6)

105 (83.3)

 Black

2 (2.2)

3 (8.8)

5 (4.0)

 Asian

2 (2.2)

6 (17.8)

8 (6.3)

 Other

6 (6.5)

2 (5.9)

8 (6.3)

Height, cm

   

 n

91

34

125

 Mean

164.7

162.3

164.0

 SD

7.30

6.99

7.27

 Median

165.0

161.0

165.0

 Min, max

147, 182

152, 180

147, 182

Weight, kg

   

 n

92

34

126

 Mean

76.37

72.09

75.21

 SD

17.590

14.766

16.925

 Median

72.65

70.20

71.85

 Min, max

46.1, 136.8

43.6, 109.5

43.6, 136.8

Body surface area, m 2

   

 n

91

34

125

 Mean

1.826

1.764

1.809

 SD

0.2021

0.1716

0.1956

 Median

1.810

1.770

1.790

 Min, max

1.47, 2.44

1.38, 2.11

1.38, 2.44

ECOG PS, n (%)

   

 0

86 (93.5)

30 (88.2)

116 (92.1)

 1

6 (6.5)

4 (11.8)

10 (7.9)

Surgical procedure, n (%)

   

 Lumpectomy

48 (52.2)

25 (73.5)

73 (57.9)

 Mastectomy

46 (50.0)

11 (32.4)

57 (45.2)

 Other

37 (40.2)

14 (41.2)

51 (40.5)

Infiltrating ductal carcinoma, n (%)

76 (82.6)

32 (94.1)

108 (85.7)

Nuclear grade, n (%)

   

 G3

49 (53.3)

20 (58.8)

69 (54.8)

 G2

31 (33.7)

14 (41.2)

45 (35.7)

Disease stage at diagnosis, n (%)

   

 IIA

42 (45.7)

12 (35.3)

54 (42.9)

 IIB

22 (23.9)

11 (32.4)

33 (26.2)

TNM staging, n (%)

   

 T1N0M0

0

12 (35.3)

12 (9.5)

 T1N1M0

20 (21.7)

0

20 (15.9)

 T2N0M0

23 (25.0)

8 (23.5)

31 (24.6)

 T2N1M0

22 (23.9)

7 (20.6)

29 (23.0)

Hormone receptor status, n (%)

   

 ER+/PR+

47 (51.1)

13 (38.2)

60 (47.6)

 ER+/PR-

14 (15.2)

12 (38.2)

26 (20.6)

 ER-/PR-

18 (31.5)

7 (20.6)

25 (19.8)

 ER-/PR+

2 (2.2)

1 (2.9)

3 (2.4)

HER2/neu receptor, n (%)

   

 Negative

91 (98.9)

0

91 (72.2)

 Positive

1 (1.1)

34 (100)

35 (27.8)

  1. Abbreviations: ECOG PS = Eastern Cooperative Oncology Group performance status; ER = estrogen receptor; HER2 = human epidermal growth factor receptor; PR = progesterone receptor; SD = standard deviation; TAC = docetaxel, doxorubicin, cyclophosphamide; TCH = docetaxel, carboplatin, trastuzumab; TNM = tumor, node, metastasis.
Back to article page